Suchergebnisse - "Schmid, Peter"

PubPharm (256)

1

Health-related quality of life with pembrolizumab plus chemotherapy vs placebo plus chemotherapy for advanced triple-negative breast cancer : KEYNOTE-355

enthalten in: Journal of the National Cancer Institute | 2024

von Cescon, D. | Schmid, P. | Rugo, H. | +16

2

Optimal [18F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial

enthalten in: Journal of nuclear medicine : official publication, Society of Nuclear Medicine | 2024

von Gebhart, G. | Keyaerts, M. | Guiot, T. | +23

3

3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain) : a randomised, open-label, phase 2 trial

enthalten in: Lancet (London, England) | 2024

von Pérez-García, J. | Cortés, J. | Ruiz-Borrego, M. | +27

4

Contribution of tumour and immune cells to PD-L1 expression as a predictive biomarker in metastatic triple-negative breast cancer : exploratory analysis from KEYNOTE-119

enthalten in: The journal of pathology. Clinical research | 2024

von Cortes, J. | Winer, E. | Lipatov, O. | +18

5

Real world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom

enthalten in: British journal of cancer | 2024

von Hanna, D. | Merrick, S. | Ghose, A. | +24

6

A plain language summary of the TROPiCS-02 study in patients with breast cancer (HR-positive/HER2-negative)

enthalten in: Future oncology (London, England) | 2024

von Rugo, H. | Bardia, A. | Marmé, F. | +4

7

First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer : Clinical and Biomarker Results

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2024

von Schmid, P. | Turner, N. | Barrios, C. | +25

8

Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple-negative breast cancer : results from the phase 3 randomised KEYNOTE-119 study

enthalten in: European journal of cancer (Oxford, England : 1990) | 2023

von Schmid, P. | Lipatov, O. | Im, S. | +18

9

TROPION-Breast02 : Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer

enthalten in: Future oncology (London, England) | 2023

von Dent, R. | Cescon, D. | Bachelot, T. | +9

10

Pembrolizumab Plus Chemotherapy Followed by Pembrolizumab in Patients With Early Triple-Negative Breast Cancer : A Secondary Analysis of a Randomized Clinical Trial

enthalten in: JAMA network open | 2023

von Takahashi, M. | Cortés, J. | Dent, R. | +17

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[26]